The CNS Pipeline Fact Book 2012

Date: February 15, 2012
Pages: 70
US$ 690.00
License [?]:
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

The CNS Pipeline Fact Book 2012
The affordable desk reference for easily reviewing the state of the global CNS drug development landscape

The CNS pipeline is second only to cancer in terms of the number of pharmaceuticals in development. Espicom has looked at Phases I, II and III of the clinical development programme and has identified more than 270 agents. These include new chemical entities and biologicals, as well as novel formulations of known drugs and new indications for approved drugs in lifecycle development. While many more are in preclinical development, this report focuses on pharmaceuticals that have progressed to clinical studies in humans.

With this report you can instantly...
  • Know what drugs for Alzheimer’s disease are in Phase II
  • Assess the CNS research portfolio for leading and emerging companies
  • Identify your research competitors and possible collaborators
  • Focus on companies who are targeting Multiple Sclerosis, and their status
  • Review drugs by specific routes of administration
Delivered to all customers in the brilliant new Espicom Interactive!

While you can choose print or pdf, you will get – at no extra charge – access in Espicom Interactive, an advanced search and display interface. Make your investment in this report really pay, with valuable and practical user benefits, including:
  • Fast full-text search results
  • “One click” export of graphs/tables to MS PowerPoint and MS Excel
  • 9 language machine translations
  • “Build your own report” facility



CNS Clinical Pipeline Overview
Neurodegenerative Diseases
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Huntingdon’s Disease
Duchenne’s Muscular Dystrophy
Cancer Pain
Neuropathic Pain
Osteoarthritis Pain
Other & Unspecified Pain Indications
Other CNS Indications
Attention Deficit Hyperactivity Disorder (ADHD)
Sleep Disorders



Collaborative R&D Partnerships
CNS Pipeline Overview by Company
CNS Pipeline Overview by Indication
Alzheimer’s Disease Pipeline Phase III
Alzheimer’s Disease Pipeline Phase II
Alzheimer’s Disease Pipeline Phase I/II
Alzheimer’s Disease Pipeline Phase I
Parkinson’s Disease Pipeline Phase III/Filed
Parkinson’s Disease Pipeline Phase II/III
Parkinson’s Disease Pipeline Phase II
Parkinson’s Disease Pipeline Phase I/II
Parkinson’s Disease Pipeline Phase I
Tardive or Levodopa-induced Dykinesia Clinical Pipeline
RRMS Pipeline, Phase III/Filed
RRMS Pipeline, Phase II/III
RRMS Pipeline, Phase II
RRMS Pipeline, Phase I
PPMS and SPMS Clinical Pipeline
MS Pipeline, Phase III
MS Pipeline, Phase II
MS Pipeline, Phase I/II
MS Pipeline, Phase I
Huntingdon’s Disease Pipeline, Phases II & III
Duchenne’s Muscular Dystrophy, Phase I/II to Phase III
Cancer Pain Pipeline, Phase III
Cancer Pain Pipeline, Phase II
Cancer Pain Pipeline, Phase I
Neuropathic Pain Indications, Phase III/Filed
Neuropathic Pain Indications, Phase II
Neuropathic Pain Indications, Phase I/II
Neuropathic Pain Indications, Phase I
Migraine Clinical Pipeline
Osteoarthritis Pain Clinical Pipeline
Acute Pain Clinical Pipeline
Chronic Pain Clinical Pipeline
Clinical Pipeline for Unspecified Pain Indications
ADHD Clinical Pipeline
Depression Indications Pipeline, Phase III & Filed
Depression Indications Pipeline, Phase II/III
Depression Indications Pipeline, Phase II
Depression Indications Pipeline, Phase I
Epilepsy Phase III & Filed
Epilepsy Phases I & II
Schizophrenia Pipeline, Phase III & Filed
Clinical Pipeline for Schizophrenia, Phase II/III
Clinical Pipeline for Schizophrenia, Phases I & II
Sleep Disorders Clinical Pipeline


CNS Clinical Pipeline by Indication (%)
CNS Clinical Pipeline by Phase
Companies with Five or More CNS Projects in Clinical Development
Alzheimer’s Disease Clinical Pipeline by Target
Alzheimer’s Clinical Pipeline by Company
Parkinson’s Disease Clinical Pipeline by Target
Multiple Sclerosis Clinical Pipeline by Mode of Action
Multiple Sclerosis Clinical Pipeline by Company
Pain Clinical Pipeline by Mode of Action
Pain Clinical Pipeline by Company
Skip to top

The World Medical Market Fact Book 2013 US$ 1,545.00 Aug, 2013 · 432 pages
The World Pharmaceutical Markets Fact Book 2013 US$ 1,545.00 Aug, 2013 · 382 pages

Ask Your Question

The CNS Pipeline Fact Book 2012
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: